D-0120 Safety and PK/PD Study in China

Summary

It is a randomized, double-blind, placebo-controlled, multiple-administration, multiple-dose, dose-escalating, phase Ib/IIa clinical study to evaluate the safety, tolerability, PK and PD of D-0120 in healthy subjects and hyperuricemia patients (gout or asymptomatic) in China.

Timeline

Start

2019-04-18

Primary completion

2021-12-31

Completion

2021-12-31

Drugs

Indications